AstraZeneca (AZN) Earns Sell Rating from UBS Group
AstraZeneca (LON:AZN)‘s stock had its “sell” rating reaffirmed by research analysts at UBS Group in a research report issued on Tuesday, ThisIsMoney.Co.Uk reports.
AZN has been the topic of several other reports. Barclays reaffirmed an “overweight” rating on shares of AstraZeneca in a report on Tuesday, February 5th. Deutsche Bank reaffirmed a “buy” rating and issued a GBX 6,900 ($90.16) target price on shares of AstraZeneca in a report on Tuesday, March 5th. Shore Capital reaffirmed a “buy” rating on shares of AstraZeneca in a report on Monday, February 25th. JPMorgan Chase & Co. set a GBX 7,100 ($92.77) target price on AstraZeneca and gave the stock a “buy” rating in a report on Tuesday, January 29th. Finally, Goldman Sachs Group set a GBX 5,000 ($65.33) target price on AstraZeneca and gave the stock a “sell” rating in a report on Wednesday, April 3rd. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and thirteen have given a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of GBX 6,362.70 ($83.14).
Shares of AZN stock opened at GBX 5,874 ($76.75) on Tuesday. AstraZeneca has a 12-month low of GBX 4,928.50 ($64.40) and a 12-month high of GBX 6,540 ($85.46). The company has a current ratio of 0.96, a quick ratio of 0.71 and a debt-to-equity ratio of 136.31. The stock has a market capitalization of $76.28 billion and a PE ratio of 34.55.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Recommended Story: What are catch-up contributions?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.